The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...

Novartis’ immunology drug Cosentyx (secukinumab) notched its sixth indication, gaining U.S. approval as a hidradenitis suppurativa (HS) therapy, the drugmaker said this week. The regulatory OK makes ...

New data suggests that disease modification with Cosentyx may be achievable for around 20% of patients following one year of treatment[1] Patients with longer disease duration before treatment with ...

Psoriasis is not simply a cosmetic problem, but a persistent, chronic (long-lasting), and sometimes distressing disease, which can affect even the smallest aspects of people`s lives on a daily ...

Novartis is counting on Cosentyx's approval in hidradenitis suppurativa and other new uses to drive the med's next phase of growth. Cosentyx may soon share the hidradenitis suppurativa (HS) field with ...

Novartis’ psoriasis drug, Cosentyx (secukinumab) received a boost after data showed it is better at clearing skin than Johnson & Johnson’s rival Stelara. Cosentyx is one of several newer drugs that ...

Novartis’ Cosentyx has a head start on the next-gen psoriasis pack, but the company is still gunning to build its lead before a raft of new competitors arrive. And now, the Swiss drugmaker has some ...

Novartis has presented new data showing that its biologic Cosentyx reduced signs and symptoms of psoriatic arthritis (PsA) while inhibiting progression of joint structural damage. Novartis has ...

Novartis NVS has announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) adopted a positive opinion for the label expansion of blockbuster ...

Getting your Trinity Audio player ready... The approved pediatric dosing for Cosentyx is 75 mg or 150 mg depending on the child’s weight at the time of dosing and is administered by subcutaneous ...